Lumicen showcases liquid PCL biostimulators at IMCAS Paris

At IMCAS Paris, Lumicen highlighted liquid polycaprolactone biostimulators as a long-lasting option for dermal rejuvenation and collagen stimulation. The company also pitched OEM/ODM manufacturing capacity, certifications and global supply support for aesthetics brands and clinics.

Why it matters: - PCL biostimulators are being positioned as a newer option for clinicians who want immediate soft tissue correction plus longer-term collagen stimulation. - The shift matters for dermatologists, plastic surgeons, clinics and distributors that want injectable products with more predictable degradation and reproducible results. - The article frames liquid PCL as a response to limits in traditional fillers and other biostimulators, especially around longevity, particle consistency and post-treatment variability.

What happened: - Lumicen presented its polymer line at the IMCAS Paris World Congress in Paris, drawing attention from international aesthetic practitioners. - The showcase centered on liquid polycaprolactone formulations for dermal rejuvenation and tissue restoration. - The company also presented itself as a partner for OEM/ODM and private label production for global aesthetic brands and clinics.

The details: - PCL is described as an active scaffolding material that is placed in the deep dermis or subdermal layers. - The material is designed to trigger a controlled, non-inflammatory tissue response that recruits macrophages and fibroblasts. - That response is intended to drive Type I and Type III collagen deposition around the degrading polymer matrix. - The article says liquid PCL avoids manual reconstitution before injection. - The article says uniform particle distribution helps reduce clumping and agglomeration. - The article says clinical efficacy typically lasts 12 to 18 months. - Compared with PLLA and PDLLA, PCL is presented as simpler to use because those products require reconstitution from powder into suspension. - Compared with PLLA and PDLLA, the article says PCL avoids variability tied to particle distribution and reduces the need for post-treatment massage. - Compared with CaHA, the article says PCL is built for longer-term collagen stimulation because CaHA degrades faster and may require more frequent touch-ups. - Lumicen’s manufacturing process is described as proprietary and focused on controlling particle shape, size consistency and surface characteristics. - The article says modern liquid PCL uses spherical, ultra-smooth microparticles suspended in sodium hyaluronate or carboxymethylcellulose. - The formulation is described as having a lower extrusion force, which supports use in finer needles and delicate areas such as the mid-face, perioral lines and neck. - The article says identical particle geometry supports a predictable hydrolysis pathway and avoids sudden structural drops or localized swelling. - The company says its production facility aligns with ISO 13485 and GMP standards. - The facility is described as having annual production capacity of up to 500,000 units. - The article says raw materials come from suppliers in France and Japan. - The company says it offers support from formulation refinement and syringe selection through packaging design and regulatory documentation. - The article says the business also has CE and ISO certifications. - More information is available at the official enterprise platform.

Between the lines: - The presentation was not only about clinical performance. It also positioned Lumicen as an industrial supplier for international expansion. - The emphasis on certifications, cleanroom controls and supply-chain consistency suggests the company is targeting buyers who need both regulatory support and manufacturing scale. - The repeated comparison with other biostimulators signals a market push to frame liquid PCL as easier to use and more predictable in practice.

What's next: - Global distributors, medical aesthetic clinics and brands may evaluate liquid PCL products as part of their injectable portfolios. - The company is likely to lean on OEM/ODM customization, regulatory documentation and supply reliability to win partners outside China. - Clinical adoption will depend on how practitioners weigh durability, handling and safety against existing filler and biostimulator options.

The bottom line: - Lumicen used IMCAS Paris to make a two-part pitch: liquid PCL as a longer-lasting biostimulator and the company itself as a scalable manufacturer for global aesthetics markets.